QTREX Quantum Ltd Dossier
Qualitative Analysis
Business overview
QTREX Quantum Ltd. (Nasdaq: QTEX), formerly known as Inspira Technologies Oxy B.H.N. Ltd. (Nasdaq: IINN) until its corporate rebranding in May 2026, is an Israel-based technology company focused on advancing Additively Manufactured Electronics (AME) for quantum computing infrastructure. The company designs and manufactures advanced cryogenic interconnect systems and high-density, thermally optimized quantum connectivity solutions used inside dilution cryostats. QTREX's proprietary single-build AME process integrates dielectric and conductive materials into monolithic 3D structures, addressing critical signal transport, routing, and thermal management bottlenecks as quantum processors scale. Alongside its primary quantum hardware focus, the company continues to advance and seek monetization opportunities for its legacy medical technology portfolio, which includes respiratory support and blood monitoring platforms.
Research as of 24 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Pivoting the company's core business model from medical devices to quantum computing hardware infrastructure, specifically focusing on Additively Manufactured Electronics (AME) for cryogenic interconnects.
Expected impact: Positions QTREX at the structural center of the cryogenic interconnect supply chain, addressing critical scaling bottlenecks (heat, noise, RF loss) inside dilution cryostats.
Establishing a dedicated domestic corporate framework in the United States to pursue federal contract execution, access non-dilutive government funding (grants, R&D programs), and engage with the U.S. Department of Defense.
Expected impact: Enables local U.S. manufacturing capabilities to support domestic production, secure supply chains, and convert federal and defense opportunities into active government contracts.
Actively working to monetize and extract value from the legacy medical technology portfolio, which includes the FDA 510(k)-cleared INSPIRA ART100 life support system and the HYLA blood sensor platforms.
Expected impact: Provides potential non-dilutive capital or licensing revenue to support the primary pivot toward quantum hardware infrastructure.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire the proprietary Additively Manufactured Electronics (AME) technology and micro-3D printing capabilities necessary to pivot into quantum computing hardware infrastructure.
Financial impact: The acquired operations generated 2025 revenues of $5.521 million but had a shortfall of revenues over direct expenses of $17.350 million.
Strategic Partnerships
To test and validate QTREX's AME-based interconnect architecture at milli-Kelvin temperatures inside a working superconducting quantum environment [3.1.5].